AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Rhea-AI Summary

AbbVie (NYSE: ABBV) will present new clinical data at the ESMO 2025 Congress (October 17–21, 2025) on its antibody-drug conjugate portfolio, highlighting telisotuzumab adizutecan (Temab-A), ABBV-706, and other ADC programs.

Key findings include Temab-A: ORR 46% in 100 MET-amplified solid tumor patients (NSCLC 69%, GEA 71%); Temab-A+bevacizumab ORR 26.7% in heavily pretreated CRC vs 0% with trifluridine/tipiracil+bev; Temab-A in PDAC ORR 24% overall (40% in prior gemcitabine–nab-paclitaxel subgroup). Observed grade ≥3 TEAEs included anemia and neutropenia across studies. ABBV-706 data show ctDNA clearance linked to higher PFS and OS and support ongoing first-line combination study.

Positive

• Temab-A overall ORR 46% in 100 MET-amplified patients
• NSCLC responses with Temab-A 69% ORR
• GEA responses with Temab-A 71% ORR
• Temab-A+bevacizumab 26.7% ORR in 3+ line CRC
• Temab-A in PDAC 24% ORR overall; 40% after 1L gemcitabine–nab-paclitaxel
• ABBV-706 ctDNA clearance associated with higher PFS and OS

Negative

• Grade ≥3 anemia 40% and neutropenia 34% in MET-amplified cohort
• Temab-A PDAC grade ≥3 anemia 38% and neutropenia 21%
• High grade ≥3 TEAE rates with Temab-A+bevacizumab (67%) similar to SOC (65%)
• Temab-A and ABBV-706 remain investigational and are not approved worldwide

• New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers.

NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),^1-3 ABBV-706,^4,5 and Emrelis™ (telisotuzumab vedotin),⁶ in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,^7-15 will be featured in multiple presentations.

"Despite recent progress in the treatment of advanced solid tumors, patients still face limited options and pressing unmet needs," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "The compelling data we are sharing at ESMO showcases how we are advancing targeted therapies across a range of solid tumors and highlights the potential of our portfolio."

Key highlights
AbbVie will present three oral presentations for Temab-A, a next-generation, investigational c-Met directed ADC with a novel topoisomerase 1 inhibitor (Top1i) payload. Phase 1 results with Temab-A both as a monotherapy and in combination across advanced, solid tumors will be presented:

• Combination with bevacizumab (Bev) in Colorectal Cancer (CRC): In biomarker unselected patients with advanced CRC who have received three or more prior lines of therapy (NCT05029882), treatment with 2.4 mg/kg dose of Temab-A plus Bev (n=30) achieved an objective response rate (ORR) of 26.7% compared to an ORR of 0% with trifluridine/tipiracil with Bev (the current standard of care (SOC), n = 20).¹ Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 67% and 65% of patients, respectively.¹
• Monotherapy in MET-Amplified Solid Tumors: Among 100 patients with advanced MET-amplified solid tumors, including non-small cell lung cancer (NSCLC) (n=29), CRC (n=22), gastroesophageal adenocarcinoma (GEA) (n=14), and 16 other tumor types (n=35) who had progressed after SOC treatment (NCT05029882), Temab-A monotherapy achieved an ORR of 46% across all dose levels and tumor types with higher responses observed in patients with NSCLC (69%) and GEA (71%).² The most common grade ≥3 TEAEs were anemia (40%) and neutropenia (34%).²
• Monotherapy in Pancreatic Ductal Adenocarcinoma (PDAC ): Among 42 biomarker unselected patients with advanced/metastatic PDAC who experienced disease progression while receiving or after completing their first-line (1L) therapy (NCT06084481), Temab-A demonstrated an ORR of 24% overall and 40% in patients who received first-line gemcitabine-nab-paclitaxel treatment.³ Grade ≥3 TEAEs occurring in ≥10% of all patients were anemia (38%) and neutropenia (21%).³

"Temab-A continues to show meaningful clinical activity across an expanding range of solid tumors and patient populations, including patients with MET-amplification and increased c-Met expression as we have seen in previously presented data," said Vivek Subbiah, M.D., Chief, Early-Phase Drug Development, Sarah Cannon Research Institute and Temab-A investigator. "These data reinforce Temab-A's potential in multiple solid tumors and thereby warrant its further clinical investigation."

AbbVie will also present new analysis from a Phase 1 study of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in relapsed/refractory small cell lung cancer (R/R SCLC) (NCT05599984).

• A post hoc analysis on data from R/R SCLC patients enrolled in the study, whose tumors had progressed after two lines of therapy (n=80), was done to compare the anti-cancer effect of ABBV-706 monotherapy vs. platinum-based SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment were analyzed in the same patients by paired Kaplan-Meier analysis. The findings suggest that ABBV-706 may have the potential to replace the platinum-based SOC as a first-line treatment in SCLC.⁴
• In the same trial, ABBV-706 treatment also resulted in rapid clearance of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Patients with 100% ctDNA clearance had significantly higher PFS and overall survival (OS) vs. patients without ctDNA clearance.⁵ These data highlight the potential of ctDNA as an early response marker in SCLC.⁵

A Phase 2 study assessing ABBV-706 in combination with atezolizumab as replacement of platinum-based chemotherapy is currently ongoing (NCT07155174) in 1L SCLC.

Details on key presentations at the ESMO 2025 Congress are available below and the full abstracts are available via the ESMO online program.

Title	Date/Time	Session	Abstract / Presentation Number
Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Patients With MET-Amplified Advanced Solid Tumors: Results From a Phase 1 Study	Sunday, October 19   2:45 - 4:15 PM CEST	Oral presentation   Proffered paper session: Developmental therapeutics Room: Bremen Auditorium - Hall 6.2	918O
Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Combination With Bevacizumab (Bev) in Patients (Pts) With 3+ Colorectal Cancer (CRC): Dose Expansion Results of a Phase 1 Study	Sunday, October 19   2:45 - 4:15 PM CEST	Mini oral session 1 : GI tumors,lower digestive   Room: Cologne Auditorium - CityCube A	731MO
Phase 1 Basket Study of Telisotuzumab Adizutecan (Temab-A), a c-Met Protein-Targeting Antibody-Drug Conjugate (ADC): Results from Patients (Pts) With Pancreatic Ductal Adenocarcinoma (PDAC)	Monday, October 20   8:30 – 10:00 AM CEST	Mini oral session 2 : GI tumours, upper digestive Room: Bonn Auditorium - Hall 7.1c	2214MO
Second progression-free survival (PFS2) and subsequent treatment in patients (pts) with folate receptor alpha (FR⍺)-positive platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) vs. investigator's choice chemotherapy (ICC): Phase 3 MIRASOL trial	Saturday, October 18   12:00 – 12:45 PM CEST	Poster	1068P
Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer	Saturday, October 18   12:00 – 12:45 PM CEST	Poster	2777P
Real World Characteristics and Outcomes of Patients with Third Line or Later Metastatic Colorectal Cancer: Magnetic-101 Study Results	Sunday, October 19   12:00 – 12:45 PM CEST	E-Poster	873eP
ABBV-706, a Seizure-Related Homolog Protein 6 (SEZ6)-Targeting Antibody-Drug Conjugate (ADC), in Patients (Pts) With Relapsed/Refractory (R/R) Small Cell Lung Cancer (SCLC): Circulating Biomarker and Molecular Response Analyses	Saturday, October 18   12:00 – 12:45 PM CEST	Poster	2778P
Seizure Related 6 Homolog (SEZ6) Expression Pattern and Prognostic Impact in a Real-World Cohort of Patients With Small Cell Lung Cancer	Saturday, October 18   12:00 – 12:45 PM CEST	E-Poster	2796eP
Companion diagnostic assay for c-Met protein overexpression (OE) to identify patients (pts) who may benefit from telisotuzumab vedotin (Teliso-V)	Saturday, October 18   12:00 – 12:45 PM CEST	Poster	1951P
Treatment outcomes in patients (pts) with advanced c- Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial	Saturday, October 18   12:00 – 12:45 PM CEST	Poster	1948P
Ocular surface disorders in patients with c-Met protein- overexpressing NSCLC treated with telisotuzumab vedotin in the LUMINOSITY study	Saturday, October 18   12:00 – 12:45 PM CEST	Poster	1950P
METRIX: International Real-World Study of c-Met Protein Overexpression in Patients With Advanced /Metastatic NSCLC	Saturday, October 18   12:00 – 12:45 PM CEST	Poster	1923P

Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.

Elahere™ (mirvetuximab soravtansine) and Emrelis™ (telisotuzumab vedotin) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.

Additional information on AbbVie clinical trials is available at https://www.clinicaltrials.gov/.

U.S. Prescribing Information for AbbVie Medicines

Please see full Prescribing information for ELAHERE™ (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS^™ (telisotuzumab vedotin-tllv)

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter) and YouTube. 

About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

References:

1. Cecchini M, Cruz-Correa M, Han SW, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Combination With Bevacizumab (Bev) in Patients (Pts) With 3+ Colorectal Cancer (CRC): Dose Expansion Results of a Phase 1 Study. Abstract 731MO presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
2. Murciano-Goroff YR, Kuboki Y, Strickler J, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Patients With MET-Amplified Advanced Solid Tumors: Results From a Phase 1 Study. Abstract 918O presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
3. Harding JJ, Strickler J, Henry J, et al. Phase 1 Basket Study of Telisotuzumab Adizutecan (Temab-A), a c-Met Protein-Targeting Antibody-Drug Conjugate (ADC): Results from Patients (Pts) With Pancreatic Ductal Adenocarcinoma (PDAC). Abstract 2214MO presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
4. Bar J, Dowlati A, Byers LA, et al. Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer. Abstract 2777P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
5. Wang S, Wang L, Luo A, et al. ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with relapsed/refractory (R/R) small cell lung cancer (SCLC): Circulating biomarker and molecular response analyses. Abstract 2778P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
6. Mansfield AS, Goldman J, Lee SH, et al. Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial. Abstract 1948P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
7. Cassim S, Chepulis L, Keenan R. et al. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. BMC Cancer. 2019; 19, 25. doi:10.1186/s12885-018-5169-9
8. Shalata W, Naamneh R, Najjar W, et al. Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer. Med Sci. 2025; 13(3):142. doi:10.3390/medsci13030142
9. Daamen LA, Molenaar IQ, and Groot VP. Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence. J Clin Med. 2023; 12(23):7485. doi:10.3390/jcm12237485
10. Cereda V and D'Andrea MR. Pancreatic cancer: failures and hopes—a review of new promising treatment approaches. Explor Target Antitumor Ther. 2025;6:1002299. doi: 10.37349/etat.2025.1002299
11. Deboever N, Jones CM, Yamashita K, et al. Advances in diagnosis and management of cancer of the esophagus. BMJ. 2024; 385 :e074962 doi:10.1136/bmj-2023-074962
12. Huang J. Overcoming Therapeutic Barriers in Esophageal Cancer Management. J Cancer Clin Trials. 2025;10,289. doi:10.37421/2577-0535.2025.9.289.
13. Nishimuni M, Claro LCL, and Braghiroli MFM. Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies. Surg Exp Pathol. 2024;7,19. doi.10.1186/s42047-024-00162-4
14. Li H, Shen M and Wang S. Current therapies and progress in the treatment of advanced gastric cancer. Front Oncol. 2024; 4:1327055. doi:10.3389/fonc.2024.1327055
15. Pathak PS, Chan G, Deming DA, et al.State-of-the-art management of colorectal cancer: Treatment advances and innovation. Am Soc Clin Oncol Educ Book, 2024; 44(3), p.e438466. doi:10.1200/EDBK_438466 

 

Contacts:
Media:	Investors:
Sourojit (Jit) Bhowmick, Ph.D.	Liz Shea
jit.bhowmick@abbvie.com	liz.shea@abbvie.com
Mabel Martinez
mabel.martinez@abbvie.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-present-new-data-at-esmo-2025-reinforcing-leadership-in-advancing-targeted-therapies-for-solid-tumors-302581936.html

SOURCE AbbVie

FAQ

When will AbbVie present ABBV (ABBV) data at ESMO 2025?

AbbVie will present data at ESMO 2025 during the Congress on October 17–21, 2025, with specific oral sessions on October 19–20.

What were the reported ORR results for Temab-A in MET-amplified tumors (ABBV)?

Temab-A showed an overall 46% ORR in 100 MET-amplified patients, with 69% in NSCLC and 71% in GEA.

How did Temab-A plus bevacizumab perform versus SOC in late-line colorectal cancer (ABBV)?

In patients with ≥3 prior lines, Temab-A 2.4 mg/kg plus bevacizumab achieved a 26.7% ORR versus 0% ORR with trifluridine/tipiracil plus bevacizumab.

What safety signals were reported for Temab-A studies from AbbVie (ABBV)?

Common grade ≥3 treatment-emergent adverse events included anemia (up to 40%) and neutropenia (up to 34%); PDAC cohort showed anemia 38% and neutropenia 21%.

What evidence supports ABBV-706 as a potential first-line option in SCLC (ABBV)?

Post hoc paired analysis found ABBV-706 PFS in relapsed SCLC compared to prior 1L platinum-based PFS suggests potential, and ctDNA clearance correlated with higher PFS and OS.

Are Temab-A and ABBV-706 approved therapies for cancer?

No; both Temab-A and ABBV-706 are investigational and not approved by any health authority worldwide.